Travere Therapeutics (TVTX) Financials

$15.34 -0.50 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$15.45 +0.11 (+0.72%)

As of 05:26 PM Eastern

Annual Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-322	-111	-278	-180	-169	-146	-103	-60	-48	117	-111
Consolidated Net Income / (Loss)	-322	-111	-278	-180	-169	-146	-103	-60	-48	117	-111
Net Income / (Loss) Continuing Operations	-321	-376	-331	-217	-169	-146	-103	-60	-48	117	-111
Total Pre-Tax Income	-321	-376	-331	-217	-189	-146	-102	-58	-58	105	-113
Total Operating Income	-324	-388	-320	-199	-176	-137	-80	-54	-58	-51	-80
Total Gross Profit	225	134	105	128	192	170	159	151	129	98	28
Total Revenue	233	145	109	132	198	175	164	155	134	100	28
Operating Revenue	233	145	109	132	198	175	164	155	134	100	28
Total Cost of Revenue	7.74	11	4.42	3.82	6.13	5.23	5.53	3.61	4.55	2.19	0.57
Operating Cost of Revenue	7.74	11	4.42	3.82	6.13	5.23	5.53	3.61	4.55	2.19	0.57
Total Operating Expenses	549	522	425	327	368	307	239	205	187	148	107
Selling, General & Admin Expense	264	266	198	126	136	129	104	101	92	80	60
Research & Development Expense	283	245	227	201	229	141	124	78	71	50	48
Restructuring Charge	2.44	11	0.00	0.00	-	-	-0.24	3.61	0.89	0.00	-
Total Other Income / (Expense), net	3.32	12	-11	-17	-13	-9.09	-22	-4.57	0.67	156	-34
Interest Expense	11	11	19	0.00	0.00	-	27	4.42	0.73	4.15	0.00
Interest & Investment Income	18	22	6.28	-18	-14	-8.77	5.50	3.23	-	-7.75	-7.44
Other Income / (Expense), net	-3.32	1.59	0.97	0.23	1.42	-0.31	-0.47	-3.38	1.39	168	-26
Income Tax Expense	0.12	0.22	0.31	0.41	-19	-0.02	0.81	1.37	-9.68	-12	-2.46
Net Income / (Loss) Discontinued Operations	-0.92	265	53	37	-	-	-	-	-	-	-
Basic Earnings per Share	($4.08)	($1.50)	($4.37)	($3.01)	($3.56)	($3.46)	($2.54)	($1.54)	($1.29)	$3.49	($4.43)
Weighted Average Basic Shares Outstanding	78.89M	74.27M	63.76M	59.83M	47.54M	42.34M	40.43M	38.77M	37.00M	33.56M	25.06M
Diluted Earnings per Share	($4.08)	($1.50)	($4.37)	($3.01)	($3.56)	($3.46)	($2.54)	($1.54)	($1.29)	$3.17	($4.43)
Weighted Average Diluted Shares Outstanding	78.89M	74.27M	63.76M	59.83M	47.54M	42.34M	40.43M	38.77M	38.29M	37.58M	25.06M
Weighted Average Basic & Diluted Shares Outstanding	88.74M	76.10M	64.74M	63.21M	47.54M	42.34M	40.43M	38.77M	37.10M	33.60M	25.06M

This table shows Travere Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-41	-61	-54	-70	-136	-90	151	-86	-86	-66	-70
Consolidated Net Income / (Loss)	-41	-60	-55	-70	-136	-90	151	-86	-86	-66	-70
Net Income / (Loss) Continuing Operations	-41	-60	-55	-70	-136	-89	-89	-102	-97	-104	-84
Total Pre-Tax Income	-41	-60	-55	-70	-136	-89	-89	-102	-96	-104	-84
Total Operating Income	-43	-61	-56	-68	-139	-94	-93	-104	-97	-106	-83
Total Gross Profit	77	72	61	52	40	40	36	31	27	-20	27
Total Revenue	82	75	63	54	41	45	37	32	31	-21	28
Operating Revenue	82	75	63	54	41	45	37	32	31	-21	28
Total Cost of Revenue	4.68	2.55	1.63	2.06	1.50	4.56	1.29	1.45	4.15	-0.88	1.11
Operating Cost of Revenue	4.68	2.55	1.63	2.06	1.50	4.56	1.29	1.45	4.15	-0.88	1.11
Total Operating Expenses	120	133	117	120	179	135	128	135	124	85	110
Selling, General & Admin Expense	73	70	66	65	64	64	68	68	66	45	52
Research & Development Expense	47	62	52	54	115	60	61	66	58	54	57
Restructuring Charge	0.00	1.40	0.12	0.65	0.26	11	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	1.49	0.40	1.31	-1.86	3.47	5.71	3.36	2.08	0.88	1.29	-1.31
Interest Expense	2.86	-	2.78	2.79	-	-	2.82	2.84	-	11	0.00
Interest & Investment Income	3.80	6.60	3.57	4.42	3.23	10	5.84	5.13	0.80	11	-0.73
Other Income / (Expense), net	0.55	-0.58	0.52	-3.50	0.24	1.37	0.34	-0.20	0.09	0.87	-0.59
Income Tax Expense	0.04	-0.07	-0.08	0.09	0.19	0.07	0.01	0.07	0.08	0.06	0.15
Net Income / (Loss) Discontinued Operations	0.00	0.00	-0.06	-0.76	-0.10	-1.58	240	16	10	-	14
Basic Earnings per Share	($0.47)	($0.71)	($0.70)	($0.91)	($1.76)	($1.07)	$1.97	($1.13)	($1.27)	($1.03)	($1.09)
Weighted Average Basic Shares Outstanding	88.36M	78.89M	77.78M	77.50M	77.14M	74.27M	76.31M	76.00M	68.17M	63.76M	64.03M
Diluted Earnings per Share	($0.47)	($0.71)	($0.70)	($0.91)	($1.76)	($1.07)	$1.97	($1.13)	($1.27)	($1.03)	($1.09)
Weighted Average Diluted Shares Outstanding	88.36M	78.89M	77.78M	77.50M	77.14M	74.27M	76.31M	76.00M	68.17M	63.76M	64.03M
Weighted Average Basic & Diluted Shares Outstanding	88.80M	88.74M	78.05M	76.49M	76.13M	76.10M	75.15M	75.01M	74.61M	64.74M	64.17M

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	1.27	-3.51	-104	81	22	-40	3.48	58	3.20	20	12
Net Cash From Operating Activities	-237	-280	-186	-15	-43	-58	-25	7.40	-3.44	-1.39	-46
Net Cash From Continuing Operating Activities	-230	-325	-261	-76	-43	-58	-25	7.40	-3.44	-1.39	-46
Net Income / (Loss) Continuing Operations	-321	-376	-331	-217	-169	-146	-103	-60	-48	117	-111
Consolidated Net Income / (Loss)	-322	-111	-278	-180	-169	-146	-103	-60	-48	117	-111
Net Income / (Loss) Discontinued Operations	-0.92	265	53	37	-	-	-	-	-	-	-
Depreciation Expense	44	39	21	13	25	20	19	18	16	13	5.40
Amortization Expense	-2.81	-5.74	0.92	13	10	9.12	3.78	1.99	1.75	1.74	5.79
Non-Cash Adjustments To Reconcile Net Income	113	44	48	34	130	62	53	31	26	-121	44
Changes in Operating Assets and Liabilities, net	-63	-24	0.88	81	-38	-3.04	2.53	17	0.93	-13	10
Net Cash From Discontinued Operating Activities	-7.45	45	75	61	-	-	-	-	-	-	-
Net Cash From Investing Activities	99	56	-33	-138	-61	20	-203	46	10	-81	-37
Net Cash From Continuing Investing Activities	99	-152	-33	-138	-61	20	-203	46	10	-81	-37
Acquisitions	-36	-42	-28	-19	-113	-15	-34	-13	-11	-40	-32
Purchase of Investments	-126	-444	-385	-547	-215	-224	-331	-102	-184	-199	-11
Sale and/or Maturity of Investments	326	335	382	434	273	259	163	162	207	9.98	6.49
Other Investing Activities, net	-65	-0.67	-0.79	0.00	0.00	-	-	-	0.00	0.00	-0.09
Net Cash From Discontinued Investing Activities	0.00	207	0.00	0.00	-	-	-	-	-	-	-
Net Cash From Financing Activities	139	219	118	232	128	-2.08	232	5.45	-3.85	102	95
Net Cash From Continuing Financing Activities	139	220	120	238	128	-2.08	232	5.45	-3.85	102	95
Repayment of Debt	0.00	0.00	-221	0.00	0.00	-	-41	-0.85	-1.36	-47	-32
Issuance of Debt	0.00	0.00	316	0.00	0.00	-	278	0.66	0.00	0.00	85
Issuance of Common Equity	137	219	23	227	134	1.78	5.31	3.65	6.01	154	48
Other Financing Activities, net	2.35	3.24	2.49	11	-5.85	-3.85	-1.13	1.99	-8.50	4.14	-1.16
Net Cash From Discontinued Financing Activities	0.00	-1.38	-2.48	-6.10	-	-	-	-	-	-	-
Cash Interest Paid	8.84	8.84	10	7.33	6.90	7.67	1.88	2.07	2.07	5.84	4.08
Cash Income Taxes Paid	0.45	0.58	1.00	-16	-3.37	0.66	0.22	7.17	7.93	9.61	0.01

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	3.36	23	4.12	-11	-15	-86	73	-91	100	-90	-28
Net Cash From Operating Activities	-42	-36	-43	-40	-119	-70	-59	-69	-81	-55	-40
Net Cash From Continuing Operating Activities	-42	-29	-43	-40	-119	-64	-74	-88	-99	-77	-92
Net Income / (Loss) Continuing Operations	-41	-60	-55	-70	-136	-89	-89	-102	-97	-86	-103
Consolidated Net Income / (Loss)	-41	-60	-55	-70	-136	-90	151	-86	-86	-66	-70
Net Income / (Loss) Discontinued Operations	0.00	0.00	-0.06	-0.76	-0.10	-1.58	240	16	10	20	-
Depreciation Expense	13	12	11	10	9.88	9.49	11	11	6.62	6.31	-0.79
Non-Cash Adjustments To Reconcile Net Income	9.92	15	7.69	80	10	13	8.23	9.68	12	6.31	-4.57
Changes in Operating Assets and Liabilities, net	-24	7.40	-6.74	-61	-2.95	8.09	-4.90	-6.60	-21	-5.02	17
Net Cash From Discontinued Operating Activities	0.00	-7.09	0.05	-0.31	-0.10	-6.10	15	19	18	22	-
Net Cash From Investing Activities	41	-80	46	29	105	-17	133	-24	-37	-37	10
Net Cash From Continuing Investing Activities	41	-80	46	29	105	-18	-73	-24	-37	-37	10
Acquisitions	-12	-9.64	-8.19	-12	-6.47	-5.51	-4.92	-3.83	-27	-4.17	-7.62
Sale and/or Maturity of Investments	53	55	54	106	111	50	88	103	94	52	112
Other Investing Activities, net	-0.08	-0.04	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	3.72	139	0.05	0.78	-0.53	0.12	-0.63	2.27	217	0.55	2.28
Net Cash From Continuing Financing Activities	3.72	139	0.05	0.78	-0.53	0.38	-0.37	2.53	218	1.16	4.15
Other Financing Activities, net	3.72	3.36	0.05	-0.53	-0.53	1.58	-0.37	0.27	1.77	-0.29	4.15
Other Net Changes in Cash	0.55	-	-	-	-0.29	-	-0.18	0.08	0.85	-	-

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	594	789	673	777	607	605	709	520	525	512	135
Total Current Assets	417	617	486	583	410	429	496	326	332	302	37
Cash & Equivalents	59	58	62	166	85	62	103	99	41	38	18
Short-Term Investments	312	509	389	387	277	336	369	201	215	192	9.56
Accounts Receivable	27	21	17	16	16	18	13	14	19	12	7.96
Inventories, net	6.20	9.41	4.52	7.31	7.61	6.08	5.62	5.35	2.83	2.54	0.80
Prepaid Expenses	13	19	12	6.72	8.14	5.02	4.14	3.11	4.83	2.38	0.81
Plant, Property, & Equipment, net	5.34	7.48	9.05	11	9.42	2.89	3.15	3.23	2.59	0.43	0.67
Total Noncurrent Assets	172	165	177	183	188	173	210	191	190	210	97
Intangible Assets	104	104	97	148	154	157	187	185	182	162	94
Other Noncurrent Operating Assets	68	60	32	34	33	15	7.71	5.56	7.36	1.86	2.27
Total Liabilities & Shareholders' Equity	594	789	673	777	607	605	709	520	525	512	135
Total Liabilities	535	588	630	475	396	384	391	227	218	212	173
Total Current Liabilities	201	178	142	124	93	95	105	86	83	87	108
Short-Term Debt	69	0.00	-	7.40	17	-	22	0.00	-	-	40
Accounts Payable	24	42	17	15	12	27	6.95	19	7.52	7.64	7.12
Accrued Expenses	86	119	96	75	57	52	50	38	35	26	29
Current Deferred Revenue	2.82	7.10	12	16	0.00	-	-	-	-	-	-
Other Current Liabilities	20	10	10	10	6.33	17	26	29	40	54	31
Total Noncurrent Liabilities	334	410	488	350	304	288	286	142	134	125	65
Long-Term Debt	310	377	376	227	215	205	195	45	44	44	43
Other Noncurrent Operating Liabilities	24	33	37	103	88	83	91	96	83	57	22
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-
Total Equity & Noncontrolling Interests	59	201	43	302	211	221	318	293	308	300	-37
Total Preferred & Common Equity	59	201	43	302	211	221	318	293	308	300	-37
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	59	201	43	302	211	221	318	293	308	300	-37
Common Stock	1,506	1,328	1,060	1,069	798	637	590	472	421	366	141
Retained Earnings	-1,447	-1,126	-1,014	-766	-586	-416	-270	-178	-113	-65	-179
Accumulated Other Comprehensive Income / (Loss)	-0.08	-1.46	-2.91	-0.56	-0.90	0.73	-1.53	-1.02	-0.49	-0.68	4.29

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	549	504	551	664	833	736	808	726
Total Current Assets	374	325	369	481	686	542	605	535
Cash & Equivalents	62	36	32	43	144	71	161	151
Short-Term Investments	260	241	293	398	490	420	400	355
Accounts Receivable	34	25	24	23	15	20	22	13
Inventories, net	3.93	6.36	5.98	4.53	21	19	6.71	7.30
Prepaid Expenses	14	16	13	13	16	12	15	8.55
Plant, Property, & Equipment, net	4.85	6.16	6.58	6.94	8.00	8.57	9.13	9.56
Total Noncurrent Assets	170	174	176	176	139	186	194	182
Intangible Assets	104	104	105	101	107	154	163	149
Other Noncurrent Operating Assets	66	69	70	74	32	31	31	32
Total Liabilities & Shareholders' Equity	549	504	551	664	833	736	808	726
Total Liabilities	516	535	536	589	553	620	619	626
Total Current Liabilities	182	190	121	173	139	136	131	131
Short-Term Debt	69	69	-	-	-	6.90	6.90	7.30
Accounts Payable	15	23	26	17	25	20	17	14
Accrued Expenses	77	84	80	140	96	89	86	88
Other Current Liabilities	21	11	10	10	10	9.90	10	9.96
Total Noncurrent Liabilities	334	345	415	416	414	484	488	495
Long-Term Debt	311	310	378	378	377	376	376	375
Other Noncurrent Operating Liabilities	23	35	37	38	32	101	104	106
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	33	-30	15	74	280	116	189	101
Total Preferred & Common Equity	33	-30	15	74	280	116	189	101
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	33	-30	15	74	280	116	189	101
Common Stock	1,522	1,357	1,349	1,338	1,319	1,307	1,292	1,049
Retained Earnings	-1,488	-1,387	-1,332	-1,262	-1,035	-1,186	-1,101	-948
Accumulated Other Comprehensive Income / (Loss)	-0.84	-1.02	-1.63	-1.89	-3.65	-3.86	-2.18	0.30

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	60.55%	32.69%	-16.97%	-33.52%	13.11%	6.75%	6.01%	15.98%	33.74%	254.19%	0.00%
EBITDA Growth	19.04%	-19.03%	-71.59%	-23.99%	-29.16%	-86.26%	-55.35%	4.00%	-129.39%	239.81%	-176.40%
EBIT Growth	15.37%	-21.23%	-60.06%	-13.99%	-26.92%	-71.00%	-40.82%	-0.62%	-148.42%	210.76%	-207.11%
NOPAT Growth	16.57%	-21.36%	-60.37%	-13.20%	-28.25%	-71.62%	-48.80%	7.60%	27.76%	-0.98%	-222.16%
Net Income Growth	-188.64%	60.00%	-54.63%	-6.29%	-15.71%	-42.61%	-71.90%	-24.69%	-140.86%	205.68%	-220.40%
EPS Growth	-172.00%	65.68%	-45.18%	15.45%	-2.89%	-36.22%	-64.94%	-19.38%	-140.69%	171.56%	-81.56%
Operating Cash Flow Growth	15.19%	-50.31%	-1,159.40%	65.39%	26.58%	-133.25%	-437.13%	315.14%	-147.73%	96.97%	-160.67%
Free Cash Flow Firm Growth	4.10%	-28.96%	-465.40%	77.30%	-139.36%	-9.92%	-421.17%	191.93%	84.89%	-51.08%	-1,785.20%
Invested Capital Growth	500.29%	193.67%	28.64%	-120.38%	199.14%	-44.11%	31.08%	-60.98%	-15.61%	508.29%	172.62%
Revenue Q/Q Growth	14.61%	84.06%	18.56%	-51.60%	38.80%	1.69%	0.98%	3.23%	5.43%	19.59%	39.90%
EBITDA Q/Q Growth	9.86%	2.57%	-3.67%	11.18%	-176.17%	-25.34%	11.46%	4.77%	6.77%	7.24%	-0.61%
EBIT Q/Q Growth	8.79%	2.99%	-6.82%	14.41%	-106.47%	-19.77%	6.52%	2.44%	4.65%	10.85%	-8.35%
NOPAT Q/Q Growth	9.37%	2.85%	-6.95%	-9.58%	-28.66%	-20.30%	11.30%	5.36%	-5.47%	-2.62%	-9.53%
Net Income Q/Q Growth	8.51%	-27.97%	-5.39%	28.00%	-117.03%	-18.45%	9.01%	-17.78%	-14.69%	29.29%	-30.99%
EPS Q/Q Growth	8.11%	-2.74%	-5.05%	36.63%	-109.41%	-17.69%	8.63%	-60.42%	-98.46%	13.21%	21.59%
Operating Cash Flow Q/Q Growth	12.77%	-5.99%	-17.51%	-728.68%	-28.11%	-1.62%	-12.19%	3,236.86%	-329.40%	79.96%	-1.55%
Free Cash Flow Firm Q/Q Growth	5.36%	9.22%	-10.90%	18.25%	-58.59%	7.95%	-16.76%	370.47%	-37.29%	-26.93%	-14.20%
Invested Capital Q/Q Growth	-4.67%	-48.89%	48.43%	16.55%	42.50%	-33.35%	21.99%	-17.51%	24.20%	14.73%	-46.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	96.68%	92.12%	95.96%	97.10%	96.91%	97.01%	96.63%	97.67%	96.59%	97.81%	97.98%
EBITDA Margin	-122.83%	-243.57%	-271.51%	-131.37%	-70.43%	-61.68%	-35.35%	-24.12%	-29.14%	132.64%	-336.03%
Operating Margin	-138.88%	-267.24%	-292.17%	-151.27%	-88.83%	-78.34%	-48.73%	-34.72%	-43.58%	-50.80%	-282.98%
EBIT Margin	-140.30%	-266.15%	-291.28%	-151.09%	-88.11%	-78.52%	-49.02%	-36.90%	-42.54%	117.49%	-375.72%
Profit (Net Income) Margin	-137.90%	-76.70%	-254.41%	-136.60%	-85.43%	-83.51%	-62.51%	-38.55%	-35.86%	117.36%	-393.36%
Tax Burden Percent	100.32%	29.62%	84.09%	83.04%	89.75%	99.99%	100.80%	102.34%	83.19%	111.16%	97.83%
Interest Burden Percent	97.97%	97.30%	103.86%	108.88%	108.04%	106.37%	126.52%	102.08%	101.34%	89.86%	107.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-11.16%	0.00%
Return on Invested Capital (ROIC)	-576.89%	0.00%	0.00%	-425.77%	-224.42%	-250.42%	-129.04%	-56.24%	-38.73%	-84.90%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-472.24%	0.00%	0.00%	-407.68%	-195.82%	-228.69%	-111.25%	-46.79%	-35.13%	-352.41%	0.00%
Return on Net Nonoperating Assets (RNNOA)	329.44%	0.00%	0.00%	355.60%	146.05%	196.13%	95.45%	36.36%	22.96%	174.14%	0.00%
Return on Equity (ROE)	-247.45%	-91.44%	-161.46%	-70.17%	-78.37%	-54.29%	-33.59%	-19.88%	-15.76%	89.25%	389.82%
Cash Return on Invested Capital (CROIC)	-719.77%	-2,627.87%	0.00%	0.00%	-324.20%	-193.83%	-155.93%	31.49%	-21.79%	-228.42%	-535.45%
Operating Return on Assets (OROA)	-47.31%	-52.90%	-44.00%	-28.78%	-28.83%	-20.96%	-13.10%	-10.94%	-10.95%	36.24%	-135.88%
Return on Assets (ROA)	-46.50%	-15.24%	-38.43%	-26.02%	-27.95%	-22.29%	-16.70%	-11.42%	-9.23%	36.20%	-142.26%
Return on Common Equity (ROCE)	-247.45%	-91.44%	-161.46%	-70.17%	-78.37%	-54.29%	-33.59%	-19.88%	-15.76%	89.25%	389.82%
Return on Equity Simple (ROE_SIMPLE)	-544.28%	-55.47%	-649.88%	-59.61%	-80.22%	-66.20%	-32.26%	-20.38%	-15.56%	39.08%	297.81%
Net Operating Profit after Tax (NOPAT)	-227	-272	-224	-140	-123	-96	-56	-38	-41	-56	-56
NOPAT Margin	-97.21%	-187.07%	-204.52%	-105.89%	-62.18%	-54.84%	-34.11%	-24.30%	-30.50%	-56.47%	-198.08%
Net Nonoperating Expense Percent (NNEP)	-104.65%	131.17%	-29.23%	-18.09%	-28.60%	-21.73%	-17.79%	-9.45%	-3.60%	267.51%	220.98%
Return On Investment Capital (ROIC_SIMPLE)	-51.75%	-47.00%	-53.51%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	3.32%	7.88%	4.04%	2.90%	3.09%	2.99%	3.37%	2.33%	3.41%	2.19%	2.02%
SG&A Expenses to Revenue	113.27%	182.83%	180.45%	95.79%	68.47%	73.54%	63.11%	65.40%	68.82%	79.63%	211.48%
R&D to Revenue	121.24%	168.68%	207.69%	152.58%	115.42%	80.40%	75.35%	50.45%	53.01%	50.48%	169.47%
Operating Expenses to Revenue	235.56%	359.36%	388.14%	248.37%	185.74%	175.36%	145.37%	132.39%	140.17%	148.62%	380.95%
Earnings before Interest and Taxes (EBIT)	-327	-387	-319	-199	-175	-138	-81	-57	-57	117	-106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-286	-354	-297	-173	-140	-108	-58	-37	-39	132	-95
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	23.01	3.36	31.49	6.29	6.59	2.76	2.93	2.83	2.32	2.32	0.00
Price to Tangible Book Value (P/TBV)	0.00	7.01	0.00	12.37	24.37	9.67	7.15	7.71	5.72	5.07	0.00
Price to Revenue (P/Rev)	5.83	4.65	12.33	14.42	7.02	3.48	5.68	5.35	5.35	6.98	11.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.95	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.81%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.31	43.31	0.00	0.00	15.33	15.12	13.49	15.24	5.22	4.48	20.40
Enterprise Value to Revenue (EV/Rev)	5.87	3.35	11.65	12.00	6.37	2.37	4.05	3.70	3.76	5.12	13.57
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.86	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.36	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	77.35	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.16	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	6.42	1.88	8.76	0.77	1.10	0.93	0.68	0.15	0.14	0.15	-2.25
Long-Term Debt to Equity	5.25	1.88	8.76	0.75	1.02	0.93	0.61	0.15	0.14	0.15	-1.16
Financial Leverage	-0.70	-1.00	-1.08	-0.87	-0.75	-0.86	-0.86	-0.78	-0.65	-0.49	-0.88
Leverage Ratio	5.32	6.00	4.20	2.70	2.80	2.44	2.01	1.74	1.71	2.47	-2.74
Compound Leverage Factor	5.21	5.84	4.36	2.94	3.03	2.59	2.54	1.78	1.73	2.22	-2.93
Debt to Total Capital	86.51%	65.26%	89.76%	43.65%	52.42%	48.08%	40.60%	13.33%	12.61%	12.73%	180.07%
Short-Term Debt to Total Capital	15.68%	0.00%	0.00%	1.38%	3.92%	0.00%	4.19%	0.00%	0.00%	0.00%	87.02%
Long-Term Debt to Total Capital	70.84%	65.26%	89.76%	42.27%	48.51%	48.08%	36.41%	13.33%	12.61%	12.73%	93.05%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	13.49%	34.74%	10.24%	56.35%	47.58%	51.92%	59.40%	86.67%	87.39%	87.27%	-80.07%
Debt to EBITDA	-1.32	-1.07	-1.26	-1.35	-1.67	-1.89	-3.75	-1.21	-1.14	0.33	-0.88
Net Debt to EBITDA	-0.03	0.54	0.25	1.84	0.92	1.79	4.63	6.84	5.43	-1.40	-0.59
Long-Term Debt to EBITDA	-1.08	-1.07	-1.26	-1.31	-1.54	-1.89	-3.36	-1.21	-1.14	0.33	-0.46
Debt to NOPAT	-1.67	-1.39	-1.68	-1.68	-1.89	-2.13	-3.88	-1.20	-1.09	-0.78	-1.50
Net Debt to NOPAT	-0.04	0.70	0.33	2.28	1.04	2.01	4.80	6.79	5.19	3.29	-1.00
Long-Term Debt to NOPAT	-1.37	-1.39	-1.68	-1.62	-1.75	-2.13	-3.48	-1.20	-1.09	-0.78	-0.77
Altman Z-Score	-2.87	-2.07	-1.61	1.05	0.76	0.19	1.42	2.20	2.14	3.25	-3.71
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.08	3.47	3.42	4.70	4.43	4.50	4.74	3.80	3.99	3.47	0.35
Quick Ratio	1.98	3.31	3.28	4.58	4.07	4.36	4.63	3.67	3.86	3.32	0.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-283	-295	-229	-40	-178	-74	-68	21	-23	-152	-100
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	-289.98%	-631.64%	-29,853.33%	-3,433.01%	834.61%	-240.97%	0.00%	-6,915.54%
Free Cash Flow to Firm to Interest Expense	-25.29	-26.02	-12.30	0.00	0.00	0.00	-2.52	4.77	-31.63	-36.57	0.00
Operating Cash Flow to Interest Expense	-21.24	-24.71	-10.02	0.00	0.00	0.00	-0.93	1.67	-4.75	-0.33	0.00
Operating Cash Flow Less CapEx to Interest Expense	-21.24	-24.71	-10.02	0.00	0.00	0.00	-0.96	1.47	-6.72	35.41	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.20	0.15	0.19	0.33	0.27	0.27	0.30	0.26	0.31	0.36
Accounts Receivable Turnover	9.66	7.68	6.72	8.28	11.68	11.42	12.38	9.57	8.63	9.78	0.00
Inventory Turnover	0.99	1.64	0.75	0.51	0.90	0.89	1.01	0.88	1.70	1.31	0.00
Fixed Asset Turnover	36.39	17.57	10.86	12.85	32.22	58.09	51.52	53.27	88.62	181.79	70.65
Accounts Payable Turnover	0.24	0.39	0.27	0.28	0.32	0.31	0.43	0.27	0.60	0.30	0.11
Days Sales Outstanding (DSO)	37.80	47.53	54.29	44.07	31.26	31.96	29.48	38.14	42.31	37.30	0.00
Days Inventory Outstanding (DIO)	367.88	222.08	488.70	713.22	407.84	407.99	362.23	413.95	214.88	278.72	0.00
Days Payable Outstanding (DPO)	1,536.76	939.84	1,339.19	1,303.84	1,154.31	1,170.45	854.95	1,339.51	607.57	1,233.07	3,412.71
Cash Conversion Cycle (CCC)	-1,131.08	-670.23	-796.20	-546.54	-715.21	-730.50	-463.24	-887.42	-350.39	-917.04	-3,412.71
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	67	11	-12	-17	82	28	49	38	96	114	19
Invested Capital Turnover	5.93	-382.71	-7.61	4.02	3.61	4.57	3.78	2.31	1.27	1.50	-7.97
Increase / (Decrease) in Invested Capital	56	23	4.81	-99	55	-22	12	-59	-18	95	45
Enterprise Value (EV)	1,368	486	1,275	1,582	1,263	416	664	573	503	511	383
Market Capitalization	1,360	676	1,350	1,900	1,391	610	933	828	714	697	327
Book Value per Share	$0.76	$2.67	$0.67	$4.93	$4.14	$5.15	$7.72	$7.46	$8.16	$8.30	($1.40)
Tangible Book Value per Share	($0.58)	$1.28	($0.84)	$2.51	$1.12	$1.47	$3.17	$2.73	$3.31	$3.80	($4.96)
Total Capital	438	578	418	536	444	426	536	338	352	344	47
Total Debt	379	377	376	234	233	205	218	45	44	44	84
Total Long-Term Debt	310	377	376	227	215	205	195	45	44	44	43
Net Debt	8.29	-190	-75	-319	-129	-194	-269	-256	-211	-186	56
Capital Expenditures (CapEx)	0.00	0.00	0.00	5.10	6.77	0.20	0.73	0.89	1.43	-148	0.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-86	-128	-106	-87	-26	-65	-58	-60	-6.78	-15	-57
Debt-free Net Working Capital (DFNWC)	285	439	344	466	335	334	414	240	249	215	-30
Net Working Capital (NWC)	216	439	344	459	318	334	391	240	249	215	-70
Net Nonoperating Expense (NNE)	95	-160	55	40	46	50	47	22	7.15	-174	55
Net Nonoperating Obligations (NNO)	8.29	-190	-55	-319	-129	-194	-269	-256	-211	-186	56
Total Depreciation and Amortization (D&A)	41	33	22	26	35	30	22	20	18	15	11
Debt-free, Cash-free Net Working Capital to Revenue	-36.91%	-88.12%	-96.81%	-65.80%	-13.33%	-37.02%	-35.33%	-39.04%	-5.08%	-14.67%	-203.80%
Debt-free Net Working Capital to Revenue	122.07%	302.17%	314.52%	353.57%	168.99%	190.27%	251.77%	154.99%	186.46%	215.18%	-105.38%
Net Working Capital to Revenue	92.61%	302.17%	314.52%	347.96%	160.22%	190.27%	238.09%	154.99%	186.46%	215.18%	-248.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.08)	($1.50)	($4.37)	($3.01)	($3.56)	($3.46)	($2.54)	($1.54)	($1.29)	$3.49	($4.43)
Adjusted Weighted Average Basic Shares Outstanding	78.89M	74.27M	63.76M	59.83M	60.24M	43.12M	40.43M	38.77M	37.00M	33.56M	26.49M
Adjusted Diluted Earnings per Share	($4.08)	($1.50)	($4.37)	($3.01)	($3.56)	($3.46)	($2.54)	($1.54)	($1.29)	$3.17	($4.43)
Adjusted Weighted Average Diluted Shares Outstanding	78.89M	74.27M	63.76M	59.83M	60.24M	43.12M	40.43M	38.77M	38.29M	37.58M	26.49M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($3.56)	($3.46)	($2.54)	$0.00	$0.00	$0.00	($4.43)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.74M	76.10M	64.74M	63.21M	47.54M	42.34M	41.41M	39.69M	38.09M	36.51M	25.06M
Normalized Net Operating Profit after Tax (NOPAT)	-225	-264	-224	-140	-123	-68	-56	-33	-24	-23	-56
Normalized NOPAT Margin	-96.48%	-181.58%	-204.52%	-105.89%	-62.18%	-38.67%	-34.22%	-21.49%	-17.67%	-22.61%	-198.08%
Pre Tax Income Margin	-137.45%	-258.96%	-302.54%	-164.51%	-95.19%	-83.52%	-62.02%	-37.67%	-43.10%	105.58%	-402.08%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-29.26	-34.10	-17.15	0.00	0.00	0.00	-3.00	-12.93	-78.38	28.27	0.00
NOPAT to Interest Expense	-20.27	-23.97	-12.04	0.00	0.00	0.00	-2.09	-8.52	-56.21	-13.59	0.00
EBIT Less CapEx to Interest Expense	-29.26	-34.10	-17.15	0.00	0.00	0.00	-3.03	-13.13	-80.35	64.02	0.00
NOPAT Less CapEx to Interest Expense	-20.27	-23.97	-12.04	0.00	0.00	0.00	-2.11	-8.72	-58.18	22.16	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8.59%	0.00%	0.00%	8.10%	-4.89%

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	97.54%	65.98%	69.56%	68.08%	33.95%	311.85%	32.13%	-40.56%	-36.30%	44.62%	-58.84%
EBITDA Growth	77.29%	40.96%	45.04%	34.71%	-42.42%	14.79%	4.47%	-64.44%	-53.63%	-12.05%	-315.50%
EBIT Growth	69.69%	33.97%	39.70%	31.64%	-42.88%	11.36%	-10.89%	-60.76%	-47.17%	-24.12%	-167.86%
NOPAT Growth	69.35%	35.55%	39.35%	34.87%	-43.00%	10.79%	-12.08%	-58.82%	-47.24%	-24.49%	-160.49%
Net Income Growth	69.70%	33.17%	-136.36%	17.78%	-57.60%	-36.99%	316.40%	-27.75%	-13.64%	-27.63%	-95.45%
EPS Growth	73.30%	33.64%	-135.53%	19.47%	-38.58%	-3.88%	280.73%	-7.62%	-5.83%	-25.61%	-84.75%
Operating Cash Flow Growth	64.54%	49.31%	28.12%	41.93%	-46.71%	-28.98%	-49.61%	-88.28%	-46.63%	-103.30%	-223.27%
Free Cash Flow Firm Growth	-11.74%	-10.65%	19.99%	-11.63%	-6.09%	-13.23%	-101.07%	-9,747.35%	-440.78%	-298.07%	-198.19%
Invested Capital Growth	739.57%	500.29%	221.84%	703.17%	2.09%	193.67%	194.50%	158.40%	178.27%	28.64%	-15.48%
Revenue Q/Q Growth	9.29%	18.90%	16.23%	30.80%	-8.18%	21.47%	15.22%	4.23%	245.23%	-175.76%	-48.17%
EBITDA Q/Q Growth	40.43%	-10.90%	27.05%	52.87%	-53.84%	-3.22%	13.34%	-2.80%	7.34%	-15.72%	-49.18%
EBIT Q/Q Growth	31.30%	-10.23%	21.87%	48.78%	-49.69%	-0.66%	11.43%	-7.06%	7.13%	-25.92%	-28.40%
NOPAT Q/Q Growth	29.74%	-8.17%	17.07%	51.38%	-47.76%	-1.78%	10.93%	-6.76%	7.82%	-27.87%	-26.21%
Net Income Q/Q Growth	31.59%	-9.95%	22.15%	48.25%	-50.89%	-159.82%	276.03%	0.81%	-31.16%	5.50%	-3.91%
EPS Q/Q Growth	33.80%	-1.43%	23.08%	48.30%	-64.49%	-154.31%	274.34%	11.02%	-23.30%	5.50%	-3.81%
Operating Cash Flow Q/Q Growth	-18.12%	15.97%	-5.63%	66.18%	-68.87%	-19.18%	14.67%	14.57%	-48.46%	-38.24%	-7.39%
Free Cash Flow Firm Q/Q Growth	-10.64%	-12.10%	17.61%	-9.35%	-9.55%	18.94%	-14.96%	-3.92%	-16.92%	-43.94%	-5,530.11%
Invested Capital Q/Q Growth	33.61%	-4.67%	4.11%	533.17%	-4.47%	-48.89%	159.80%	-19.52%	187.65%	48.43%	-60.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	94.28%	96.59%	97.41%	96.19%	96.36%	89.87%	96.53%	95.49%	86.58%	0.00%	96.03%
EBITDA Margin	-35.88%	-65.82%	-70.57%	-112.45%	-312.08%	-185.03%	-217.75%	-289.49%	-293.52%	0.00%	-301.18%
Operating Margin	-52.21%	-81.21%	-89.27%	-125.11%	-336.53%	-209.13%	-249.59%	-322.87%	-315.23%	0.00%	-294.23%
EBIT Margin	-51.54%	-81.99%	-88.44%	-131.57%	-335.96%	-206.09%	-248.69%	-323.49%	-314.95%	0.00%	-296.31%
Profit (Net Income) Margin	-50.44%	-80.58%	-87.14%	-130.11%	-328.86%	-200.12%	406.35%	-265.96%	-279.50%	0.00%	-248.11%
Tax Burden Percent	100.09%	99.87%	99.95%	101.21%	100.22%	101.86%	-168.93%	84.06%	89.48%	63.09%	83.00%
Interest Burden Percent	97.77%	98.41%	98.57%	97.71%	97.67%	95.33%	96.73%	97.81%	99.18%	99.60%	100.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-198.51%	-337.36%	-274.53%	-407.65%	-3,457.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	169.42%	-317.78%	-254.73%	-324.42%	-3,425.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-9.78%	221.69%	160.10%	136.30%	3,149.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-208.29%	-115.67%	-114.43%	-271.35%	-308.07%	-91.44%	-45.76%	-225.07%	-145.41%	-161.46%	-129.51%
Cash Return on Invested Capital (CROIC)	-473.32%	-719.77%	-645.30%	-877.95%	-2,838.92%	-2,627.87%	-1,479.61%	-3,497.90%	-2,567.88%	0.00%	0.00%
Operating Return on Assets (OROA)	-23.26%	-27.65%	-26.91%	-36.30%	-71.09%	-40.96%	-25.17%	-29.83%	-35.36%	0.00%	-36.44%
Return on Assets (ROA)	-22.76%	-27.17%	-26.52%	-35.90%	-69.59%	-39.77%	41.13%	-24.52%	-31.38%	0.00%	-30.52%
Return on Common Equity (ROCE)	-208.29%	-115.67%	-114.43%	-271.35%	-308.07%	-91.44%	-45.76%	-225.07%	-145.41%	-161.46%	-129.51%
Return on Equity Simple (ROE_SIMPLE)	-690.70%	0.00%	1,154.05%	-963.28%	-217.53%	0.00%	-31.11%	-263.93%	-152.71%	0.00%	-262.46%
Net Operating Profit after Tax (NOPAT)	-30	-43	-39	-47	-97	-66	-65	-73	-68	-74	-58
NOPAT Margin	-36.55%	-56.85%	-62.49%	-87.58%	-235.57%	-146.39%	-174.71%	-226.01%	-220.66%	0.00%	-205.96%
Net Nonoperating Expense Percent (NNEP)	-367.93%	-19.58%	-19.79%	-83.23%	-31.90%	-19.81%	112.93%	-9.21%	-9.08%	4.34%	-5.24%
Return On Investment Capital (ROIC_SIMPLE)	-7.25%	-9.71%	-	-	-	-11.41%	-	-	-	-17.67%	-
Cost of Revenue to Revenue	5.72%	3.41%	2.59%	3.81%	3.64%	10.13%	3.47%	4.51%	13.42%	0.00%	3.97%
SG&A Expenses to Revenue	89.12%	92.93%	104.33%	119.70%	155.23%	141.12%	182.78%	211.84%	213.51%	0.00%	186.71%
R&D to Revenue	57.37%	82.99%	82.16%	100.40%	277.05%	132.60%	163.34%	206.52%	188.30%	0.00%	203.54%
Operating Expenses to Revenue	146.49%	177.80%	186.68%	221.30%	432.90%	299.00%	346.11%	418.36%	401.81%	0.00%	390.26%
Earnings before Interest and Taxes (EBIT)	-42	-61	-56	-71	-139	-93	-92	-104	-97	-105	-83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-29	-49	-44	-61	-129	-83	-81	-93	-91	-98	-85
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	48.45	23.01	0.00	41.31	7.82	3.36	2.40	9.84	7.70	31.49	15.65
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	7.01	3.88	0.00	55.46	0.00	0.00
Price to Revenue (P/Rev)	5.81	5.83	5.26	3.52	3.72	4.65	8.50	16.40	15.85	12.33	17.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	18.30	20.31	16.57	10.00	48.14	43.31	18.80	122.82	121.65	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	6.02	5.87	5.76	3.82	3.31	3.35	5.23	14.85	13.91	11.65	15.73
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	11.56	6.42	-12.43	24.96	5.10	1.88	1.35	3.29	2.02	8.76	3.80
Long-Term Debt to Equity	9.46	5.25	-10.18	24.96	5.10	1.88	1.35	3.23	1.99	8.76	3.73
Financial Leverage	-0.06	-0.70	-0.63	-0.42	-0.92	-1.00	-1.00	-1.02	-1.01	-1.08	-1.11
Leverage Ratio	11.34	5.32	5.36	9.78	5.59	6.00	4.10	5.55	4.12	4.20	3.68
Compound Leverage Factor	11.09	5.24	5.29	9.56	5.46	5.72	3.96	5.43	4.09	4.18	3.71
Debt to Total Capital	92.04%	86.51%	108.75%	96.15%	83.60%	65.26%	57.39%	76.69%	66.93%	89.76%	79.16%
Short-Term Debt to Total Capital	16.68%	15.68%	19.71%	0.00%	0.00%	0.00%	0.00%	1.38%	1.21%	0.00%	1.51%
Long-Term Debt to Total Capital	75.36%	70.84%	89.04%	96.15%	83.60%	65.26%	57.39%	75.31%	65.73%	89.76%	77.65%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	7.96%	13.49%	-8.75%	3.85%	16.40%	34.74%	42.61%	23.31%	33.07%	10.24%	20.84%
Debt to EBITDA	-2.06	-1.32	-1.19	-1.07	-0.98	-1.07	-1.04	-1.05	-1.16	-1.26	-1.33
Net Debt to EBITDA	-0.31	-0.03	-0.32	-0.15	0.16	0.54	0.71	0.29	0.54	0.25	0.43
Long-Term Debt to EBITDA	-1.69	-1.08	-0.98	-1.07	-0.98	-1.07	-1.04	-1.03	-1.14	-1.26	-1.31
Debt to NOPAT	-2.39	-1.67	-1.51	-1.37	-1.25	-1.39	-1.35	-1.41	-1.56	-1.68	-1.83
Net Debt to NOPAT	-0.36	-0.04	-0.40	-0.19	0.21	0.70	0.92	0.40	0.73	0.33	0.59
Long-Term Debt to NOPAT	-1.95	-1.37	-1.24	-1.37	-1.25	-1.39	-1.35	-1.38	-1.53	-1.68	-1.79
Altman Z-Score	-1.28	-1.40	-2.29	-2.25	-1.97	-0.85	-0.50	-0.86	-0.07	-0.56	0.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.05	2.08	1.71	3.04	2.78	3.47	4.92	3.99	4.63	3.42	4.08
Quick Ratio	1.95	1.98	1.59	2.89	2.68	3.31	4.66	3.77	4.46	3.28	3.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-109	-99	-88	-107	-98	-89	-110	-96	-92	-79	-55
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	-49,076.83%	0.00%	0.00%	-591,340.00%	-2,309,900.00%	-12,875.71%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-38.21	0.00	-31.69	-38.31	0.00	0.00	-38.99	-33.66	0.00	-7.15	0.00
Operating Cash Flow to Interest Expense	-14.77	0.00	-15.31	-14.43	0.00	0.00	-20.96	-24.37	0.00	-4.96	0.00
Operating Cash Flow Less CapEx to Interest Expense	-14.77	0.00	-15.31	-14.46	0.00	0.00	-20.97	-24.38	0.00	-4.96	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.34	0.30	0.28	0.21	0.20	0.10	0.09	0.11	0.15	0.12
Accounts Receivable Turnover	9.58	9.66	10.24	7.92	7.04	7.68	5.79	3.77	5.07	6.72	7.09
Inventory Turnover	2.58	0.99	0.72	0.76	1.57	1.64	0.43	0.44	0.97	0.75	0.61
Fixed Asset Turnover	46.38	36.39	28.74	23.45	19.38	17.57	8.99	7.49	9.31	10.86	8.76
Accounts Payable Turnover	0.68	0.24	0.41	0.41	0.53	0.39	0.31	0.37	0.37	0.27	0.43
Days Sales Outstanding (DSO)	38.10	37.80	35.65	46.09	51.88	47.53	63.00	96.84	71.94	54.29	51.47
Days Inventory Outstanding (DIO)	141.47	367.88	507.54	479.43	232.95	222.08	853.37	826.60	375.76	488.70	599.84
Days Payable Outstanding (DPO)	536.50	1,536.76	896.71	886.69	693.04	939.84	1,177.94	994.64	998.43	1,339.19	855.37
Cash Conversion Cycle (CCC)	-356.93	-1,131.08	-353.52	-361.17	-408.21	-670.23	-261.57	-71.19	-550.72	-796.20	-204.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	90	67	71	68	11	11	22	8.45	11	-12	-23
Invested Capital Turnover	5.43	5.93	4.39	4.65	14.68	-382.71	-123.59	-23.22	-63.03	-7.61	-4.26
Increase / (Decrease) in Invested Capital	79	56	49	59	0.22	23	45	23	24	4.81	-3.12
Enterprise Value (EV)	1,647	1,368	1,171	679	516	486	413	1,038	1,277	1,275	1,452
Market Capitalization	1,590	1,360	1,070	626	579	676	671	1,146	1,456	1,350	1,576
Book Value per Share	$0.37	$0.76	($0.40)	$0.20	$0.96	$2.67	$3.73	$1.56	$2.92	$0.67	$1.57
Tangible Book Value per Share	($0.80)	($0.58)	($1.76)	($1.18)	($0.35)	$1.28	$2.30	($0.51)	$0.41	($0.84)	($0.76)
Total Capital	412	438	348	393	452	578	657	500	572	418	483
Total Debt	379	379	379	378	378	377	377	383	383	376	382
Total Long-Term Debt	311	310	310	378	378	377	377	376	376	376	375
Net Debt	57	8.29	101	53	-63	-190	-258	-108	-179	-75	-124
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.08	0.00	0.00	0.01	0.00	0.63	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-62	-86	-74	-78	-133	-128	-88	-78	-80	-106	-95
Debt-free Net Working Capital (DFNWC)	260	285	203	248	308	439	547	413	481	344	411
Net Working Capital (NWC)	192	216	135	248	308	439	547	406	474	344	404
Net Nonoperating Expense (NNE)	11	18	16	23	39	24	-216	13	18	-8.12	12
Net Nonoperating Obligations (NNO)	57	8.29	101	53	-63	-190	-258	-108	-179	-55	-124
Total Depreciation and Amortization (D&A)	13	12	11	10	9.88	9.49	11	11	6.62	6.91	-1.37
Debt-free, Cash-free Net Working Capital to Revenue	-22.58%	-36.91%	-36.44%	-43.73%	-85.53%	-88.12%	-111.32%	-111.74%	-87.47%	-96.81%	-103.13%
Debt-free Net Working Capital to Revenue	95.23%	122.07%	99.93%	139.44%	197.69%	302.17%	692.94%	591.28%	523.79%	314.52%	445.29%
Net Working Capital to Revenue	70.09%	92.61%	66.21%	139.44%	197.69%	302.17%	692.94%	581.41%	516.28%	314.52%	437.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.47)	($0.71)	($0.70)	($0.91)	($1.76)	($1.07)	$1.97	($1.13)	($1.27)	($1.03)	($1.09)
Adjusted Weighted Average Basic Shares Outstanding	88.36M	78.89M	77.78M	77.50M	77.14M	74.27M	76.31M	76.00M	68.17M	63.76M	64.03M
Adjusted Diluted Earnings per Share	($0.47)	($0.71)	($0.70)	($0.91)	($1.76)	($1.07)	$1.97	($1.13)	($1.27)	($1.03)	($1.09)
Adjusted Weighted Average Diluted Shares Outstanding	88.36M	78.89M	77.78M	77.50M	77.14M	74.27M	76.31M	76.00M	68.17M	63.76M	64.03M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.80M	88.74M	78.05M	76.49M	76.13M	76.10M	75.15M	75.01M	74.61M	64.74M	64.17M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-42	-39	-47	-97	-58	-65	-73	-68	-74	-58
Normalized NOPAT Margin	-36.55%	-55.54%	-62.35%	-86.73%	-235.13%	-128.69%	-174.71%	-226.01%	-220.66%	0.00%	-205.96%
Pre Tax Income Margin	-50.39%	-80.68%	-87.18%	-128.55%	-328.15%	-196.47%	-240.54%	-316.40%	-312.37%	0.00%	-298.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.74	0.00	-20.03	-25.54	0.00	0.00	-32.70	-36.63	0.00	-9.51	0.00
NOPAT to Interest Expense	-10.46	0.00	-14.15	-17.00	0.00	0.00	-22.97	-25.59	0.00	-6.71	0.00
EBIT Less CapEx to Interest Expense	-14.74	0.00	-20.03	-25.57	0.00	0.00	-32.70	-36.64	0.00	-9.51	0.00
NOPAT Less CapEx to Interest Expense	-10.46	0.00	-14.15	-17.03	0.00	0.00	-22.98	-25.60	0.00	-6.71	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Travere Therapeutics' Financials

When does Travere Therapeutics's financial year end?

According to the most recent income statement we have on file, Travere Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Travere Therapeutics' net income changed over the last 10 years?

Travere Therapeutics' net income appears to be on an upward trend, with a most recent value of -$321.55 million in 2024, rising from -$110.94 million in 2014. The previous period was -$111.40 million in 2023. See where experts think Travere Therapeutics is headed by visiting Travere Therapeutics' forecast page.

What is Travere Therapeutics's operating income?

Travere Therapeutics's total operating income in 2024 was -$323.83 million, based on the following breakdown:

Total Gross Profit: $225.43 million
Total Operating Expenses: $549.26 million

How has Travere Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' total revenue changed from $28.20 million in 2014 to $233.18 million in 2024, a change of 726.8%.

How much debt does Travere Therapeutics have?

Travere Therapeutics' total liabilities were at $535.05 million at the end of 2024, a 9.0% decrease from 2023, and a 209.8% increase since 2014.

How much cash does Travere Therapeutics have?

In the past 10 years, Travere Therapeutics' cash and equivalents has ranged from $18.20 million in 2014 to $165.75 million in 2021, and is currently $58.54 million as of their latest financial filing in 2024.

How has Travere Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' book value per share changed from -1.40 in 2014 to 0.76 in 2024, a change of -154.3%.

Related Companies

This page (NASDAQ:TVTX) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Financials

Frequently Asked Questions About Travere Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Financials

Annual Income Statements for Travere Therapeutics

Quarterly Income Statements for Travere Therapeutics

Annual Cash Flow Statements for Travere Therapeutics

Quarterly Cash Flow Statements for Travere Therapeutics

Annual Balance Sheets for Travere Therapeutics

Quarterly Balance Sheets for Travere Therapeutics

Annual Metrics And Ratios for Travere Therapeutics

Quarterly Metrics And Ratios for Travere Therapeutics

Frequently Asked Questions About Travere Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools